Biogen | BIIB - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Bayer EUR -3.37B 2.21B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 343.6M 46.34M 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03